Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study

Advances in Therapy

Volumn 33, Issue 3, 2016, Pages 410-422

  Sun, Jing ^a   Yuan, Yaozong ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

China; Gastroenterology; Mesalazine; Randomized controlled trial; Remission phase; Ulcerative colitis

Indexed keywords

MESALAZINE; DELAYED RELEASE FORMULATION; ENTERIC COATED TABLET; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERIC COATED TABLET; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MODIFIED RELEASE TABLET; MULTICENTER STUDY; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SINGLE BLIND PROCEDURE; ULCERATIVE COLITIS; CHINA; CLINICAL TRIAL; COLITIS, ULCERATIVE; DELAYED RELEASE FORMULATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHINA; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; SINGLE-BLIND METHOD; TABLETS, ENTERIC-COATED;

EID: 84959094845     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0304-y     Document Type: Article

References (14)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guideline in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–85.
2. Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs. 1989;38:500–23.
3. Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196–200.
4. Mardini HA, Lindsay DC, Deighton CM, Record CO. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut. 1987;28:1084–9.
5. Riley SA, Tavares IA, Bennett A, Mani V. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br J Clin Pharmacol. 1988;26:173–7.
6. Chinese Medical Association. Chinese consensus on standard management of inflammatory bowel diseases. Zhonghua Xiao Hua Za Zhi. 2007;27:545–50.
7. Jing Sun, Yaozong Yuan. Mesalazine modified-release tablet in the treatment of ulcerative colitis in active phase: a multi-center, single-blinded and randomized controlled study. Chin J Dig. 2015;35:252–5.
8. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–8.
9. Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16:1575–82.
10. Prantera C, Kohn A, Campieri M, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther. 2009;30:908–18.
11. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010;138:1286–96, 1296.e1–3.
12. ®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. 2012;107:1064–77.
13. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther. 2005;21:1111–9.
14. Jing Sun, Yaozong Yuan. Mesalazine modified-release tablet in the treatment of ulcerative colitis in remission phase: a multi-center, single-blinded and randomized controlled study. Chin J Dig. 2015;35:256–9.